Literature DB >> 1264542

A therapeutic trial of fatty acid supplementation in cystic fibrosis.

R B Elliott.   

Abstract

Seven children with cystic fibrosis (CF) have been treated for at least one year with intravenously administered soya oil emulsion. In all, an improvement of at least one biochemical abnormality in character with the disease appeared. The children's clinical course remains benign. This course is remarkably better than that of other children with CF treated without Intralipid in Auckland in the same period, though a placebo effect cannot be discounted. It is postulated that intravenous supplementation with essential fatty acid in CF may in turn partially correct an error of metabolism of prostaglandins present in the disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1264542

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  10 in total

Review 1.  Rationale of modern dietary recommendations in cystic fibrosis.

Authors:  J M Littlewood; A MacDonald
Journal:  J R Soc Med       Date:  1987       Impact factor: 5.344

2.  International Symposium on Inborn Errors of Metabolism in Humans, 2-5 September 1980, Interlaken, Switzerland. Work in progress.

Authors: 
Journal:  J Inherit Metab Dis       Date:  1981       Impact factor: 4.982

3.  Fatty acid composition of serum lecithin in healthy children.

Authors:  C Alling; B Westerberg
Journal:  Eur J Pediatr       Date:  1981-10       Impact factor: 3.183

4.  Abnormal fatty acid pattern of the plasma cholesterol ester fraction in cystic fibrosis patients with and without pancreatic insufficiency.

Authors:  V Rogiers; A Vercruysse; I Dab; D Baran
Journal:  Eur J Pediatr       Date:  1983-10       Impact factor: 3.183

5.  Serum fatty acid profiles in cystic fibrosis patients and their parents.

Authors:  A B Christophe; W J Warwick; R T Holman
Journal:  Lipids       Date:  1994-08       Impact factor: 1.880

6.  Absorption of triglycerides with defined or random structure by rats with biliary and pancreatic diversion.

Authors:  M S Christensen; A Müllertz; C E Høy
Journal:  Lipids       Date:  1995-06       Impact factor: 1.880

7.  Biotin-responsive immunoregulatory dysfunction in multiple carboxylase deficiency.

Authors:  A Fischer; A Munnich; J M Saudubray; S Mamas; F X Coudé; C Charpentier; F Dray; J Frézal; C Griscelli
Journal:  J Clin Immunol       Date:  1982-01       Impact factor: 8.317

Review 8.  Nutrition in Cystic Fibrosis-Some Notes on the Fat Recommendations.

Authors:  Birgitta Strandvik
Journal:  Nutrients       Date:  2022-02-18       Impact factor: 5.717

Review 9.  Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis.

Authors:  Réginald Philippe; Valerie Urbach
Journal:  Int J Mol Sci       Date:  2018-09-21       Impact factor: 5.923

Review 10.  Is the ENaC Dysregulation in CF an Effect of Protein-Lipid Interaction in the Membranes?

Authors:  Birgitta Strandvik
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.